In this downloadable slideset from the CCO Pancreatic Cancer VA meeting series, Thomas H. Cartwright, MD, and Milind Javle, MD, provide expert perspective on optimizing treatment choices for patients with advanced pancreatic cancer.
Expert answers to frequently asked questions about modern clinical management of pancreatic cancer, including diagnosis and screening, neoadjuvant treatment, first-line and second-line therapy, and novel approaches such as combining immunotherapy with chemotherapy or radiation.
Oral edoxaban was noninferior to subcutaneous dalteparin regarding combined risk of recurrent VTE or major bleeding in patients with cancer-associated VTE.
Compared with dalteparin, rivaroxaban was associated with a lower incidence of VTE recurrence within 6 months but a higher incidence of clinically relevant bleeding events.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.